Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®
June 03, 2021 13:20 ET | Catalyst Pharmaceuticals, Inc.
- Without an NOC, Ruzurgi® is without a Marketing Authorization in Canada - Matter Remanded Back to Health Canada to Provide a More Transparent Record of Its Decision in Light of Firdapse®’s Data...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
May 19, 2021 08:03 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update
May 10, 2021 17:29 ET | Catalyst Pharmaceuticals, Inc.
-Firdapse® Q1 2021 Net Revenues of $30.2 Million -First Quarter 2021 GAAP Net Income of $7.7 Million; Non-GAAP Net Income of $11.6 Million -Recently Received Orphan Drug Designation for Firdapse® in...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Hold First Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 11th, 2021
May 03, 2021 08:05 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces $40 Million Share Repurchase Program
March 22, 2021 08:03 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
March 15, 2021 17:26 ET | Catalyst Pharmaceuticals, Inc.
- Firdapse® Q4-20 Net Revenues of $31.0 Million, FY-20 Net Revenues of $119.1 Million - GAAP Net Income of $75.0 Million for Fiscal Year 2020 - $140.3 Million in Cash and Investments and No Funded...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 16th, 2021
March 04, 2021 11:00 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021
February 22, 2021 08:03 ET | Catalyst Pharmaceuticals, Inc.
Catalyst Supporting Facebook Live Panel on Living with a Rare Disease Hosted by The MightyCatalyst Kicks off Rare Reason Campaign CORAL GABLES, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion for Long-Term Success and Provides Corporate Update
January 06, 2021 08:07 ET | Catalyst Pharmaceuticals, Inc.
Company to Expand R&D Focus for Pipeline Growth to include Earlier Stage Programs and Validated Technology Platforms Firdapse® 2020 Net Revenues Estimate of approximately $118 Million; about 16%...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
November 09, 2020 17:20 ET | Catalyst Pharmaceuticals, Inc.
- Firdapse® Third Quarter Net Revenues of $29.2 Million - Company Ends Third Quarter with $127.1 Million in Cash and Investments - U.S. Patent Issued for Firdapse® and Expires April 7, 2034 -...